-
公开(公告)号:US07875633B2
公开(公告)日:2011-01-25
申请号:US11990889
申请日:2006-08-23
申请人: Akira Naya , Toshihiro Sakamoto , Yuji Haga , Norikazu Otake
发明人: Akira Naya , Toshihiro Sakamoto , Yuji Haga , Norikazu Otake
IPC分类号: A61K31/444 , A61K31/4439 , A61K31/5377 , A61K31/4545 , A61P9/00 , A61P25/00 , A61P3/00 , C07D213/64 , C07D401/02 , C07D413/02 , C07D401/14
CPC分类号: C07D213/69 , C07D213/64 , C07D401/10 , C07D413/10
摘要: A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH═CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.
摘要翻译: 作为活性成分,含有式(I)所示的化合物:其中,R 1和R 2分别独立地表示氢原子,低级烷基等,或者与连接有L,Z 2和R 1的氮原子一起形成 可以形成脂族氮杂环基,并且R 1和R 2与它们所连接的氮原子一起形成脂族氮杂环基; X表示次甲基或氮原子; Y表示-CH 2 -O-,-CH = CH-等; Z1表示单键,C1-4亚烷基等; Z2表示单键或C1-4亚烷基; L表示亚甲基,C3-8亚环烷基等; Ar表示芳族碳环基等。 该化合物可用作中枢神经系统疾病,心血管疾病或代谢疾病的药物。
-
公开(公告)号:US20090137587A1
公开(公告)日:2009-05-28
申请号:US11990889
申请日:2006-08-23
申请人: Akira Naya , Toshihiro Sakamoto , Yuji Haga , Norikazu Otake
发明人: Akira Naya , Toshihiro Sakamoto , Yuji Haga , Norikazu Otake
IPC分类号: A61K31/444 , C07D213/64 , C07D401/02 , C07D413/02 , A61K31/4439 , A61P9/00 , A61P25/00 , A61P3/00 , C07D401/14 , A61K31/5377 , A61K31/4545
CPC分类号: C07D213/69 , C07D213/64 , C07D401/10 , C07D413/10
摘要: A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH═CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.
摘要翻译: 作为活性成分,含有式(I)所示的化合物:其中,R 1和R 2分别独立地表示氢原子,低级烷基等,或者与连接有L,Z 2和R 1的氮原子一起形成 可以形成脂族氮杂环基,并且R 1和R 2与它们所连接的氮原子一起形成脂族氮杂环基; X表示次甲基或氮原子; Y表示-CH 2 -O - , - CH-CH-等; Z1表示单键,C1-4亚烷基等; Z2表示单键或C1-4亚烷基; L表示亚甲基,C3-8亚环烷基等; Ar表示芳族碳环基等。 该化合物可用作中枢神经系统疾病,心血管疾病或代谢疾病的药物。
-
公开(公告)号:US07732456B2
公开(公告)日:2010-06-08
申请号:US10591373
申请日:2005-03-04
申请人: Norikazu Otake , Yuji Haga , Akira Naya , Sayaka Mizutani , Akio Kanatani
发明人: Norikazu Otake , Yuji Haga , Akira Naya , Sayaka Mizutani , Akio Kanatani
IPC分类号: A61K31/444 , C07D401/02
CPC分类号: C07D213/69 , C07D237/16 , C07D239/52 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/14 , C07D451/02 , C07D471/04
摘要: The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R1 and R2 may be same or different and stands for H, etc., or R1 and R2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X1-X3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X4-X7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y1 and Y3 may be same or different and stand for single bond, —O—, —NR—, —S—, etc; Y2 stands for lower lkylene, etc.; R stands for H, etc., L stands for methylene; Z1 and Z2 may be same or different and stand for single bond or lower alkylene; or R1, L and Z2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R1 binds; and Ar stands for aromatic carbocyclic group, etc.].
摘要翻译: 本发明提供由通式(I)表示的吡啶酮衍生物[在该式中,R 1和R 2可以相同或不同,代表H等,或者R 1和R 2可以与脂族含氮杂环基一起形成 他们绑定的N X1-X3可以相同或不同,代替次甲基或N,但不是全部同时代表氮; X4-X7可以相同或不同,代表次甲基或N,条件是它们中的三个或更多不同时代表N; Y1和Y3可以相同或不同,代表单键,-O-,-NR-,-S-等; Y2代表低级亚烷基等; R代表H等,L代表亚甲基; Z 1和Z 2可以相同或不同,代表单键或低级亚烷基; 或R1,L和Z2可以与R1结合的N形成脂族含氮杂环基; 和Ar代表芳族碳环基团等]。
-
公开(公告)号:US20070208046A1
公开(公告)日:2007-09-06
申请号:US10591373
申请日:2005-03-04
申请人: Norikazu Otake , Yuji Haga , Akira Naya , Sayaka Mizutani , Akio Kanatani
发明人: Norikazu Otake , Yuji Haga , Akira Naya , Sayaka Mizutani , Akio Kanatani
IPC分类号: A61K31/513 , A61K31/444 , A61K31/4412 , C07D403/02 , C07D401/02
CPC分类号: C07D213/69 , C07D237/16 , C07D239/52 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/14 , C07D451/02 , C07D471/04
摘要: The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R1 and R2 may be same or different and stands for H, etc., or R1 and R2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X1-X3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X4-X7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y1 and Y3 may be same or different and stand for single bond, —O—, —NR—, —S—, etc; Y2 stands for lower alkylene, etc.; R stands for H, etc., L stands for methylene; Z1 and Z2 may be same or different and stand for single bond or lower alkylene; or R1, L and Z2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R1 binds; and Ar stands for aromatic carbocyclic group, etc.].
摘要翻译: 本发明提供由通式(I)表示的吡啶酮衍生物[在式中,R 1和R 2可以相同或不同,代表H等, 或R 1和R 2可以与它们所键合的N一起形成脂族含氮杂环基; X 1 -X 3可以相同或不同,代表次甲基或N,但并不全部同时代表氮; X 4 -X 7可以相同或不同,代表次甲基或N,条件是它们中的三个或更多个不同时代表N; Y 1和Y 3可以相同或不同,代表单键,-O-,-NR-,-S-等; Y 2代表低级亚烷基等; R代表H等,L代表亚甲基; Z 1和Z 2可以相同或不同,代表单键或低级亚烷基; 或R 1,L和Z 2可以与R 1结合的N形成脂族含氮杂环基; 和Ar代表芳族碳环基团等]。
-
公开(公告)号:US07452908B2
公开(公告)日:2008-11-18
申请号:US10838340
申请日:2004-05-05
申请人: Yufu Sagara , Minaho Uchiyama , Akira Naya , Toshifumi Kimura , Tomoshige Numazawa , Toru Fujikawa , Norikazu Otake , Kazuhito Noguchi
发明人: Yufu Sagara , Minaho Uchiyama , Akira Naya , Toshifumi Kimura , Tomoshige Numazawa , Toru Fujikawa , Norikazu Otake , Kazuhito Noguchi
IPC分类号: A61K31/445 , C07D211/32
CPC分类号: C07D401/12 , C07D207/16 , C07D211/26 , C07D401/14 , C07D471/10 , C07D493/10
摘要: This invention relates to compounds which are represented by the general formula [I] [in which A stands for a group of the following formula [ao] or [b0] Ar1, Ar2 and Ar3 stand for optionally substituted phenyl; k stands for 0 or 1; m, n and s stand for 0, 1 or 2; R1 stands for hydrogen or optionally substituted lower alkyl; R2, R3, R4 and R5 either stand for hydrogen or optionally substituted lower alkyl, or R2 and R3, or R4 and R5 together stand for trimethylene and the like; R60 stands for hydrogen, alkyl, or the like; R61 and R71 either stand for alkyl and the like, or together stand for trimethylene and the like; X stands for carbonyl or methylene; Y stands for nitrogen or methine; and Q− stands for anion], and the like. The compounds of the invention exhibit selective antagonism to muscarinic M3 receptors, and therefore are useful as safe and effective agents showing little side effect, for treating diseases of the respiratory, urinary and digestive systems.
摘要翻译: 本发明涉及由通式[I]表示的化合物[其中A代表下列通式[a]或[b] 0 i> Ar 1,Ar 2和Ar 3代表任选取代的苯基; k代表0或1; m,n和s代表0,1或2; R 1表示氢或任选取代的低级烷基; R 2,R 3,R 4和R 5均代表氢或任选取代的低级烷基,或 R 2和R 3,或R 4和R 5一起代表三亚甲基等; R 60代表氢,烷基等; R 61和R 71均代表烷基等,或一起代表三亚甲基等; X代表羰基或亚甲基; Y代表氮或次甲基; 和Q 代表阴离子]等。 本发明的化合物对毒蕈碱M 3受体表现出选择性拮抗作用,因此可用作治疗呼吸,泌尿和消化系统疾病的副作用小的安全有效的药剂。
-
公开(公告)号:US06809108B1
公开(公告)日:2004-10-26
申请号:US10031716
申请日:2002-03-26
申请人: Yufu Sagara , Minaho Uchiyama , Akira Naya , Toshifumi Kimura , Tomoshige Numazawa , Toru Fujikawa , Norikazu Otake , Kazuhito Noguchi
发明人: Yufu Sagara , Minaho Uchiyama , Akira Naya , Toshifumi Kimura , Tomoshige Numazawa , Toru Fujikawa , Norikazu Otake , Kazuhito Noguchi
IPC分类号: A61K31445
CPC分类号: C07D401/12 , C07D207/16 , C07D211/26 , C07D401/14 , C07D471/10 , C07D493/10
摘要: This invention relates to compounds which are represented by the general formula [I] [in which A stands for a group of the following formula [a0] or [b0] Ar1, Ar2 and Ar3 stand for optionally substituted phenyl; k stands for 0 or 1; m, n and a stand for 0, 1 or 2; R1 stands for hydrogen or optionally substituted lower alkyl; R2, R3, R4 and R5 either stand for hydrogen or optionally substituted lower alkyl, or R2 and R3, or R4 and R5 together stand for trimethylene and the like; R60 stands for hydrogen, alkyl, or the like; R61 and R71 either stand for alkyl and the like, or together stand for trimethylene and the like; X stands for carbonyl or methylene; Y stands for nitrogen or methine; and Q− stands for anion], and the like. The compounds of the invention exhibit selective antagonism to muscarinic M3 receptors, and therefore are useful as safe and effective agents showing little side effect, for treating diseases of the respiratory, urinary and digestive systems.
摘要翻译: 本发明涉及由通式[I]表示的化合物[其中A代表下式[a0]或[b0] Ar 1的基团,Ar 2和Ar 3代表 任选取代的苯基; k代表0或1; m,n和a代表0,1或2; R 1代表氢或任选取代的低级烷基; R 2,R 3,R 4和R 5分别代表氢或任选取代的低级烷基,或者R 2和R 3,或R 4和R 5, 一起代表三亚甲基等; R 60代表氢,烷基等; R 61和R 71代表烷基等,或一起代表三亚甲基等; X代表羰基或亚甲基; Y代表氮或次甲基; 并且Q 1表示阴离子]等。本发明的化合物对毒蕈碱性M3受体表现出选择性拮抗作用,因此可用作治疗副作用小的安全有效药物,用于治疗呼吸道,尿和尿的疾病 消化系统。
-
公开(公告)号:US07164024B2
公开(公告)日:2007-01-16
申请号:US10475447
申请日:2002-04-19
申请人: Takeru Yamakawa , Yoshio Ogino , Yufu Sagara , Kenji Matsuda , Akira Naya , Toshifumi Kimura , Norikazu Otake
发明人: Takeru Yamakawa , Yoshio Ogino , Yufu Sagara , Kenji Matsuda , Akira Naya , Toshifumi Kimura , Norikazu Otake
IPC分类号: A61K31/44
CPC分类号: C07D401/14 , C07D409/14
摘要: This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I] [in which R1 and R2 stand for, e.g., hydrogen atoms; R3a, R3b, R4, R5 stand for, e.g., hydrogen atoms and alkyl groups; R6 stands for e.g., aryl or heteroaryl groups; A ring stands for 5- to 8-membered aliphatic heterocyclic ring containing one nitrogen atom; and Z stands for carbonyl group or sulfonyl group]. The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease, drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.
摘要翻译: 本发明涉及由通式[I] [其中R 1,R 2和R 2]的化合物代表的例如氢原子的苯并咪唑酮衍生物; R 3a,R 3b,R 4,R 5表示例如氢原子和烷基; R 6表示例如芳基或杂芳基; 环代表含有一个氮原子的5-至8-元脂族杂环; Z代表羰基或磺酰基]。 本发明的苯并咪唑酮衍生物对毒蕈碱性乙酰胆碱受体表现出拮抗作用,可用作帕金森病,药物诱发的帕金森综合征,肌张力障碍,运动不良,胰腺炎,胆石,胆囊炎,胆汁运动障碍,贲门失弛缓症,疼痛,瘙痒的治疗剂和/或预防 ,胆碱能性荨麻疹,肠易激综合征,呕吐,恶心,眩晕,梅尼埃病,运动病和尿紊乱。
-
公开(公告)号:US08044070B2
公开(公告)日:2011-10-25
申请号:US12540534
申请日:2009-08-13
申请人: Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
发明人: Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
IPC分类号: A61K31/445 , C07D211/00
CPC分类号: C07D401/12 , A61K31/4545 , A61K31/501 , A61K31/506 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04
摘要: Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.
摘要翻译: 提供式(I)化合物及其药学上可接受的盐:其中X1,X2和X3各自独立地表示N或CH; W表示下式(II):或下式(III):Y表示式(IV)的基团:所述化合物具有组胺H3受体拮抗或反向激动活性,可用于治疗和/或 预防肥胖,糖尿病,激素分泌障碍,睡眠障碍等
-
公开(公告)号:US20060178375A1
公开(公告)日:2006-08-10
申请号:US10561115
申请日:2004-06-24
申请人: Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
发明人: Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
IPC分类号: A61K31/506 , C07D413/14 , C07D403/14
CPC分类号: C07D401/12 , A61K31/4545 , A61K31/501 , A61K31/506 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04
摘要: Compound of the formula: (I) [wherein each of X1, X2, and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful of the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep, disorder, etc.
摘要翻译: 式(I)的化合物[其中X 1,X 2和X 3各自独立地表示N或CH,W表示 式(II):(II)或式(III):III),Y表示式(IV):(IV)]的基团,或其药理学上可接受的盐。 该化合物显示组胺受体H3拮抗剂或反向激动剂活性,并且可用于治疗和/或预防肥胖症,糖尿病,激素分泌异常,睡眠,障碍等。
-
公开(公告)号:US20100210637A1
公开(公告)日:2010-08-19
申请号:US12540534
申请日:2009-08-13
申请人: Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
发明人: Norikazu Ohtake , Akira Naya , Yuji Haga , Makoto Jitsuoka , Takuya Suga , Ryo Yoshimoto , Shigeru Tokita , Akio Kanatani
IPC分类号: A61K31/5377 , C07D403/12 , A61K31/506 , A61P3/10 , A61P3/04 , A61P1/16 , A61P3/06 , A61P9/10 , C07D401/12 , A61K31/4545 , C07D413/14 , A61K31/501
CPC分类号: C07D401/12 , A61K31/4545 , A61K31/501 , A61K31/506 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04
摘要: Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.
摘要翻译: 提供式(I)化合物及其药学上可接受的盐:其中X1,X2和X3各自独立地表示N或CH; W表示下式(II):或下式(III):Y表示式(IV)的基团:所述化合物具有组胺H3受体拮抗或反向激动活性,可用于治疗和/或 预防肥胖,糖尿病,激素分泌障碍,睡眠障碍等
-
-
-
-
-
-
-
-
-